Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

R Löfberg, P Rutgeerts, H Malchow, C Lamers, A Danielsson, G Olaison, D Jewell, O Ostergaard Thomsen, H Lorenz-Meyer, H Goebell, H Hodgson, T Persson, C Seidegård

Unit of Gastroenterology, Karolinska Institute, Huddinge, Sweden.

BACKGROUND AND AIMS: To evaluate the efficacy and safety of the topical corticosteroid budesonide, given in an oral controlled release formulation for maintenance of remission in patients with ileal and ileocaecal Crohn's disease (CD). PATIENTS AND METHODS: Out of 176 patients with active CD who had achieved remission (CD activity index score < or = 150) after 10 weeks' treatment with either budesonide or prednisolone, 90 were randomised to continue with once daily treatment of 6 mg budesonide, or 3 mg budesonide or placebo for up to 12 months in a double blind, multicentre trial. Time to symptomatic relapse was calculated using Kaplan-Meier estimates. Morning plasma cortisol was measured at clinic visits and a corticotropin stimulation test was performed after three months of treatment. RESULTS: Thirty two patients were allocated to the 6 mg budesonide group, 31 to the 3 mg group, and 27 to the placebo group. After three months, 19 per cent of the patients in the 6 mg group had relapsed, compared with 45 per cent in the 3 mg group and 44 per cent in the placebo group (p = 0.047). The corresponding results after 12 months was 59 per cent in the 6 mg budesonide group, 74 per cent in the 3 mg group, and 63 per cent in the placebo group (p = 0.44). The median time to relapse or discontinuation was 258 days in the 6 mg group, 139 days in the 3 mg group, and 92 days in the placebo group (p = 0.021). Mean morning plasma cortisol values increased from entry in all three groups with no statistically significant differences at 12 months. All 13 patients remaining in the placebo group after three months had a normal corticotropin stimulation response, compared with 18 of 23 patients in the 6 mg, and 19 of 21 in the 3 mg budesonide groups (p = 0.14). Acne and moon face were slightly more common in the budesonide groups. CONCLUSION: 6 mg budesonide once daily is significantly more efficacious than placebo in prolonging time to relapse in CD, and causes only minor systemic side effects.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Schnitzler, F, Fidder, H, Ferrante, M, Noman, M, Arijs, I, Van Assche, G, Hoffman, I, Van Steen, K, Vermeire, S, Rutgeerts, P (2009). Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58: 492-500 [Abstract] [Full Text]  
• Hockenbery, D. M., Cruickshank, S., Rodell, T. C., Gooley, T., Schuening, F., Rowley, S., David, D., Brunvand, M., Berryman, B., Abhyankar, S., Bouvier, M., McDonald, G. B., for the orBec GVHD Study Group, (2007). A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109: 4557-4563 [Abstract] [Full Text]  
• Travis, S P L, Stange, E F, Lemann, M, Oresland, T, Chowers, Y, Forbes, A, D'Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J, for the European Crohn's and Colitis Organisation, (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55: i16-i35 [Abstract] [Full Text]  
• Olesen, M, Eriksson, S, Bohr, J, Jarnerot, G, Tysk, C (2004). Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 53: 536-541 [Abstract] [Full Text]  
• Tumulty, J. W., Broussard, J. D., Steiner, J. M., Peterson, M. E., Williams, D. A. (2004). Clinical Effects of Short-Term Oral Budesonide on the Hypothalamic-Pituitary-Adrenal Axis in Dogs With Inflammatory Bowel Disease. Journal of the American Animal Hospital Association 40: 120-123 [Abstract] [Full Text]  
• Hofer, K. N (2003). Oral Budesonide in the Management of Crohn's Disease. The Annals of Pharmacotherapy 37: 1457-1464 [Abstract] [Full Text]  
• (2002). CORRECTION. Gut 51: 616-616 [Full Text]  
• Farthing, M J G (2002). Ileal Crohn's disease is best treated by surgery. Gut 51: 13-14 [Full Text]  
• Campieri, M (2002). New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50: iii43-46 [Abstract] [Full Text]  
• Cortot, A, Colombel, J-F, Rutgeerts, P, Lauritsen, K, Malchow, H, Hamling, J, Winter, T, Van Gossum, A, Persson, T, Pettersson, E (2001). Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 48: 186-190 [Abstract] [Full Text]  
• Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., Hanauer, S. B., McDonald, J. W.D., The North American Crohn's Study Group Investigato, (2000). A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. NEJM 342: 1627-1632 [Abstract] [Full Text]  
• Rampton, D. S (1999). Regular review: Management of Crohn's disease. BMJ 319: 1480-1485 [Full Text]  
• Bickston, S. J., Cominelli, F. (1998). Treatment of Crohn's Disease at the Turn of the Century. NEJM 339: 400-402 [Full Text]  
• Wyllie, R., Sarigol, S. (1998). The Treatment of Inflammatory Bowel Disease in Children. CLIN PEDIATR 37: 421-425  
• Gross, V, Andus, T, Ecker, K W, Raedler, A, Loeschke, K, Plauth, M, Rasenack, J, Weber, A, Gierend, M, Ewe, K, Scholmerich, J, Budesonide Study Group, (1998). Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. Gut 42: 493-496 [Abstract] [Full Text]  
• (1997). Controlled-release budesonide in Crohn's disease. DTB 35: 30-31 [Abstract] [Full Text]